Q3 2025 Earnings November 5, 2025 Forward Looking Statements & Non-GAAP Financial Measures This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or Lyft's future financial or operating performance. In some cases, you can identify forward looking statements because the ...

McKesson Corporation Second Quarter Fiscal 2026 Earnings Call November 5, 2025 1 © 2021 McKesson Corporation. All rights reserved. Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approxim ...

Financial Performance - Total revenue increased to $216.8 million, a 113% year-over-year increase[10] - Molecular Profiling Services revenue increased to $207.6 million, a 121% year-over-year increase[10] - Pharma R&D Services revenue increased to $9.2 million, an 18% year-over-year increase[10] - Clinical ASP improved by 87%, from $2,184 to $4,089[13] - Achieved Positive Adjusted EBITDA of $51.2 million and GAAP Net Income of $24.3 million[13] - Achieved Positive Free Cash Flow of $55.3 million[13] - Q3 2025 gross margin was 68%, a ~2,432 bps improvement[13] Clinical Volume and Data - Clinical volume grew by 18%, completing 50,763 clinical cases[13] - The dataset surpassed 959,000+ genomic profiles and 660,000+ matched profiles including over 577,000 WES and 628,000 WTS[13] Guidance - Updated CY 2025 total revenue guidance to $720 - $730 million, representing 75-77% year-over-year growth[50] - Updated CY 2025 clinical therapy selection volume growth to 21-22% year-over-year[50] Partnership - 97 POA sites with now over 1,150 publications[13]

Q3 2025 EARNINGS SUPPLEMENT NOVEMBER 5, 2025 LEGAL DISCLAIMER This earnings supplement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future financial and operating results of the Company, estimates of future EBITDA, the timing and performance of new store openings, future reductions in cost of capital and leverage ratio, our ability to conduct future accretive acquisitions and our pipeline of new store loc ...

Financial Performance - Revenues decreased by 7% year-over-year to $93.9 million in Q1 FY26[17] - Product revenue experienced a significant decrease of 23% to $37.1 million[17] - Service revenue showed strong growth, increasing by 7% to $56.8 million[17] - Reported gross margin was 28.3%, but adjusting for China margin deferral, it was 29.4%[17, 21] - Adjusted EBITDA was negative $4.1 million, a decrease of 231%[17] China Joint Venture Impact - A net deferral of $1.1 million in Q1 was due to a higher mix of shipments to the China joint venture[21, 25] - The cumulative deferred margin in the balance sheet related to the China joint venture is $18.02 million[23] - Without considering the China impact, the adjusted EBITDA margin would be -3% instead of the reported -4%[23] Guidance and New Products - The company maintains its FY26 revenue guidance of $471 million to $485 million, representing a growth of 3% to 6%[26] - The company maintains its FY26 Adjusted EBITDA guidance of $31 million to $35 million, representing a growth of 10% to 25%[26] - Accuray Stellar, a configuration of the Radixact® Treatment Delivery System, was launched at ASTRO[14, 21]

Financial Performance - Consolidated revenue increased by 3% year-over-year to $841 million[9,63], driven by Gaming and iGaming revenue growth[63] - Consolidated AEBITDA increased by 18% year-over-year to $375 million[9,63], with margin expansion across all businesses[63] - Adjusted NPATA increased by 25% year-over-year to $153 million[9,63], benefiting from revenue growth and expanded AEBITDA margins[63] - Adjusted NPATA per share (EPSa) increased 35% year-over-year to $1.81[9,63] Segment Results - Gaming revenue increased by 4% year-over-year to $558 million[19,23], driven by Gaming operations and Table products[23] - SciPlay revenue decreased by 4% year-over-year to $197 million[19,23], but AEBITDA increased by 8% to $71 million[23] - iGaming revenue increased by 16% year-over-year to $86 million[19,23], with AEBITDA increasing by 42% to $34 million[23] Key Metrics - Recurring revenue accounted for approximately 69% of consolidated revenue, totaling $580 million, a 14% year-over-year increase[9] - North America installed base increased 42% year-over-year to 47,240 units, including over 11,250 units from Grover Gaming[29,33] - Wagers processed through OGS in iGaming grew 23% year-over-year to $28 billion[52,53] Capital Allocation - $111 million was returned to shareholders through share repurchases in 3Q25[9] - The company maintains a net debt leverage ratio of 3.5x[78]

Investor Presentation Q3 2025 Earnings Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer November 5, 2025 Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward- looking statements herein or in previous disclosures ...

Q2 FY26 Earnings Presentation Nov 5, 2025 Cautionary Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, regarding LiveRamp's (the "Company") future business prospects. These statements involve risks and uncertainties that could cause the Company's actual results to differ materially, including, but not limited to competit ...

Q3 2025 Business & Financial Highlights November 5, 2025 2 IonQ Q3 2025 Update Copyright © 2025 IonQ, Inc. All Rights Reserved. Unprecedented Momentum and Scale The Quantum Leader in Every Metric That Matters Oak Ridge National Laboratory Copyright © 2025 IonQ, Inc. All Rights Reserved. Important Information Forward-Looking Statements and Other Information This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, including ...

Financial Performance - Total revenues are projected to be between $4175 million and $4275 million[31] - Non-GAAP Adjusted Net Income (ANI) is guided to be between $475 million and $525 million[31] - Adjusted Earnings Per Share (EPS) is expected to be in the range of $765 to $845[31] - Cash reserves at the end of 3Q25 stand at $2 billion[32] - September Year-To-Date (YTD) operating cash flow reached $993 million[32] - Neuroscience revenues accounted for 43% of the total, with Xywav revenues at $431 million, showing an 11% year-over-year growth[88] - Oncology revenues contributed 48%, amounting to $288 million, a 1% increase year-over-year[88] Product Performance - Epidiolex revenues grew by 20% year-over-year, reaching $303 million in 3Q25[17, 46] - Total sleep therapeutic area revenue was $520 million in 3Q25[38] - Rylaze revenues increased by 1% year-over-year, totaling $100 million in 3Q25[51, 52] - Modeyso achieved $11 million in net product sales in 3Q25 following its launch[69]